Gilead’s quarterly revenue falls 4%, COVID oral drug fails to pass trials 

Gilead Sciences said fourth-quarter revenue fell 4 per cent due to lower sales of its HIV drugs and Veklury, a drug contained in them to treat COVID-19, and the company forecast weaker-than-expected sales in 2024. 

Share This Post:

POPULAR POSTS
FOLLOW US
Like Us On Facebook
Follow Us On Twitter
Subscribe To Our Channel
TikTok
LIVE STREAM